• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Hum Vaccin Immunother . Estimating the potential public health and economic impact of vaccination timing: A modeling study of COVID-19 vaccination

tetano

Editor, Senior Moderator
Hum Vaccin Immunother


. 2026 Dec;22(1):2668795.
doi: 10.1080/21645515.2026.2668795. Epub 2026 May 12.
Estimating the potential public health and economic impact of vaccination timing: A modeling study of COVID-19 vaccination in the United Kingdom

Cale Harrison[SUP] 1 [/SUP], Ben Yarnoff[SUP] 2 [/SUP], Rebecca Butfield[SUP] 1 [/SUP], Jingyan Yang[SUP] 3 [/SUP], Charlie Reynard[SUP] 4 [/SUP]


Affiliations
Abstract

This study evaluated the public health and economic impact of timely protection against COVID-19 infection with an adapted vaccine in the United Kingdom. A static decision-tree model was used to estimate the impact of timely protection with an autumn dose and a spring dose and assess how delays in the start of the vaccination program affect the impact. The model examined a hypothetical year based on the average age-stratified incidence and severity reported in public health surveillance data for the 2022/2023 and the 2023/2024 seasons. Other age-stratified parameters vaccine coverage, cost, and vaccine effectiveness parameters were informed by literature. Timely protection with the autumn dose for those aged ≥75 y and the high-risk population aged 18-74 was estimated to avert 1.0 million cases, 15,642 hospitalization, 3,897 deaths, 82,977 post-COVID condition cases, £179 million in direct medical costs, and £195 million in productivity losses. Timely protection with the spring dose for those aged ≥75 y and the high-risk population aged 18-74 was estimated to avert 98,446 cases, 1,477 hospitalization, 279 deaths, 8,357 post-COVID condition cases, £6 million in direct medical costs, and £14 million in productivity losses. Delays in the start of the vaccination program substantially reduced the estimated public health and economic impact of vaccination for both the autumn and spring doses. Adapted vaccines for COVID-19 remain an important public health tool for reducing the health and economic burden. However, delays in the start of vaccination campaigns may erode the potential impact.

Keywords: COVID-19 vaccination; United Kingdom; decision-analytic model; economic evaluation; vaccine policy; vaccine timing.

 
Back
Top